Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Genitourinary Cancers
•
Thoracic Malignancies
•
Medical Oncology
•
Brain Metastases
•
Renal Cell Carcinoma
•
Non-small cell lung cancer
Would you offer systemic therapy after rendered NED from SRS to isolated CNS metastases in a patient with prior curative intent treatment of lung adenocarcinoma and clear cell RCC?
Related Questions
Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
